NC-KBI-BIOPHARMA
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality Officer, strengthening KBI’s expertise in Quality and Regulatory Affairs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240401053397/en/
Peter Carbone, KBI Biopharma Chief Quality Officer (Photo: Business Wire)
A highly respected and successful industry leader, Peter brings over 35 years of experience in operations, quality, and technology leadership in a diverse range of areas in the life sciences spectrum, including biotechnology, pharmaceuticals, and advanced therapies. Peter will lead KBI’s Quality and Regulatory Affairs team, spearheading compliance and regulatory initiatives for customers worldwide and positioning KBI to provide the services, expertise, and leadership to partner with health authorities on regulatory policy.
"We have made a commitment to establishing KBI Biopharma as a thought leader and catalyst for change in Regulatory Affairs within the biopharma sector,” said J.D. Mowery, President & CEO of KBI Biopharma. "Peter's addition to our team bolsters our expertise in quality and regulatory compliance and facilitates our continued transformation in support of our current and future customers. His passion for making a difference in the world, coupled with his drive to develop and deliver innovative products that improve patients’ lives, makes him an invaluable asset to KBI.”
“I am thrilled to join KBI Biopharma during a time of significant evolution for the company,” said Peter Carbone, Chief Quality Officer of KBI Biopharma. “We are poised for remarkable advancements in the biopharma industry, and I look forward to working with this talented team to drive innovation, ensure quality, deliver exceptional results, and ultimately make a meaningful impact on patients’ lives worldwide.”
Prior to joining KBI, Peter led engineering, operations, and quality organizations at major pharmaceutical companies, including Bayer, Amgen, Allergan, Novartis, Acorda, and the Center of Breakthrough Medicines. He holds a BS in Chemical Engineering from Rensselaer Polytechnic Institute.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401053397/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Published Data Confirms Nemluvio® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis17.12.2025 07:00:00 CET | Press release
Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab’s fast onset of action and improvement of itch and sleep disturbance in patients with moderate-to-severe atopic dermatitis and prurigo nodularis1 Significant improvements in itch were observed as early as 48 hours after initial treatment and steadily increased through to Day 141 Nemolizumab is the first approved monoclonal antibody that specifically targets and inhibits the signalling of IL-31 – a neuroimmune cytokine that drives itch and other symptoms in atopic dermatitis and prurigo nodularis2-4 Nemolizumab is approved by multiple regulatory authorities around the world for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis, including in the U.S. and EU5,6 Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s r
Mori Memorial Foundation’s Global Power City Index 2025 Sees City Rankings Shift Due to Tourism Gains in East Asia and Inflationary Pressures in the West17.12.2025 04:00:00 CET | Press release
The Mori Memorial Foundation’s Institute for Urban Strategies, a research body established by Mori Building, Tokyo’s leading urban landscape developer, today published its annual Global Power City Index (GPCI) 2025, a report evaluating the urban competitiveness of 48 major cities worldwide. The report also includes the GPCI–Financial Centers index, an assessment of cities as international financial centers, and the new GPCI–Startup Ecosystems index, which assesses the competitiveness of startup environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216187692/en/ 48 Major Cities Evaluated in Mori Memorial Foundation’s GPCI-2025 Report This year’s report highlights the remarkable rise of East Asian cities and the stagnation of several Western cities, showing how global challenges, such as geopolitical tensions and regional disparities in inflation, are greatly impacting the performance of major cities worldwide. The r
GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners17.12.2025 03:00:00 CET | Press release
300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicable diseases. Collaboration supports Indonesian Government’s agenda to enhance diagnostic access and build national healthcare resilience. Multi-year agreement builds on GE HealthCare’s continued investment in local manufacturing, capability building and knowledge transfer to strengthen Indonesia’s healthcare ecosystem. GE HealthCare (Nasdaq: GEHC) today announced it will supply more than 300 CT (computed tomography) scanners under Indonesia’s Strengthening Indonesia’s Health Referral Network (SIHREN) program to deliver equitable, high-quality care to more than 280 million Indonesians. As part of a competitively awarded, multi-year contract, GE HealthCare will supply the advanced CT scanners to public hospitals across all 38 provinces, including urban and remote areas. The CT scanner procurement under SIHREN was conducted through a fully co
IDWS 2025 Concludes with Focus on Global Knowledge Exchange, Financial Opportunities, and Scalable Water Solutions16.12.2025 20:03:00 CET | Press release
The 4th Innovation Driven Water Sustainability Conference (IDWS) 2025 concluded on Wednesday in Jeddah, confirming its status as one of the world’s most influential platforms for shaping the future of water innovation, sustainability, and security. Gathering senior global policymakers and international industry leaders, this year’s edition has advanced critical dialogue on safeguarding the planet’s most vital resource, with Saudi Arabia at the forefront. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216483490/en/ Investors, innovators, and global institutions gather in Saudi to outline how capital, collaboration, and governance can accelerate long term water sustainability (Photo: AETOSWire) Among the most consequential engagements were a series of meetings that brought together discussions powered by SWA, centred on shared challenges, knowledge exchange, and exploring opportunities within the global water ecosystem. Att
OAG Appoints ex-Skyscanner Executive Filip Filipov as New Chief Executive Officer16.12.2025 17:00:00 CET | Press release
OAG announces today the appointment of Filip Filipov, ex-Skyscanner executive, as new Chief Executive Officer. Filip Filipov currently serves as the company’s Chief Operating Officer and takes over from Phil Callow who has chosen to step down having completed thirteen transformational years at the helm of OAG to pursue his many other interests. Since joining in 2024, Filipovhas played a leading role in the company’s ambitious next phase of growth and ongoing acceleration. He will now lead OAG into a new era defined by advanced data products and AI-driven intelligence. Before joining OAG, Filipov held senior roles in travel technology and big-data consulting, including on Skyscanner’s executive team. Filip Filipov said: “It’s a privilege to step into this role and lead a company with such a strong heritage and reputation. I’m excited for what’s ahead and committed to serving our customers with the reliability, service, and innovation they depend on.” Chairman of OAG, Gehan Talwatte, com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom